$1.08 Billion is the total value of EcoR1 Capital, LLC's 41 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 128.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MRTX | Buy | MIRATI THERAPEUTICS INC | $73,300,000 | +167.0% | 1,000,000 | +54.5% | 6.76% | +146.0% |
CRSP | Buy | CRISPR THERAPEUTICS AG | $67,092,000 | +1024.4% | 1,878,277 | +799.3% | 6.18% | +936.0% |
XNCR | Buy | XENCOR INC | $63,966,000 | +78.9% | 2,059,429 | +108.2% | 5.90% | +64.8% |
New | FIBROGEN INCput | $54,350,000 | – | 1,000,000 | +100.0% | 5.01% | – | |
RARE | New | ULTRAGENYX PHARMACEUTICAL INC | $34,534,000 | – | 497,899 | +100.0% | 3.18% | – |
New | MIRATI THERAPEUTICS INCcall | $25,574,000 | – | 348,900 | +100.0% | 2.36% | – | |
MYOK | Buy | MYOKARDIA INC | $24,881,000 | +117.3% | 478,574 | +104.2% | 2.29% | +100.2% |
GOSS | New | GOSSAMER BIO INC | $16,731,000 | – | 772,096 | +100.0% | 1.54% | – |
CHMA | Buy | CHIASMA INC | $15,828,000 | +1240.2% | 3,043,827 | +701.5% | 1.46% | +1136.4% |
HARP | New | HARPOON THERAPEUTICS INC | $12,656,000 | – | 1,336,423 | +100.0% | 1.17% | – |
MRSN | New | MERSANA THERAPEUTICS INC | $12,098,000 | – | 2,300,000 | +100.0% | 1.12% | – |
RUBY | Buy | RUBIUS THERAPEUTICS INC | $11,697,000 | +22.9% | 646,228 | +9.1% | 1.08% | +13.1% |
SURF | Buy | SURFACE ONCOLOGY INC | $10,797,000 | +12.6% | 2,263,488 | +0.1% | 1.00% | +3.8% |
ADRO | New | ADURO BIOTECH INC | $7,719,000 | – | 1,939,390 | +100.0% | 0.71% | – |
VCEL | New | VERICEL CORP | $2,294,000 | – | 131,001 | +100.0% | 0.21% | – |
SNNAQ | New | SIENNA BIOPHARMACEUTICALS INC | $1,856,000 | – | 800,000 | +100.0% | 0.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
XENCOR ORD | 25 | Q3 2023 | 12.6% |
ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
PROTHENA ORD | 20 | Q3 2023 | 28.0% |
IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-03 |
SC 13G/A | 2024-04-08 |
3 | 2024-03-26 |
SC 13G/A | 2024-03-26 |
SC 13G | 2024-03-11 |
SC 13D | 2024-02-22 |
SC 13G | 2024-02-16 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.